Global Induced Pluripotent Stem Cells (iPSCs) Market 2025 by Company, Regions, Type and Application, Forecast to 2031

Global Induced Pluripotent Stem Cells (iPSCs) Market 2025 by Company, Regions, Type and Application, Forecast to 2031

According to our (Global Info Research) latest study, the global Induced Pluripotent Stem Cells (iPSCs) market size was valued at US$ 118 million in 2024 and is forecast to a readjusted size of USD 260 million by 2031 with a CAGR of 12.0% during review period.

Induced pluripotent stem cells (also known as iPS cells or iPSCs) are a type of pluripotent stem cell that can be generated directly from adult cells. The opportunities concerning a wide range of diseases including neurodegenerative, metabolic and cardiovascular diseases in a dish for cheaper and faster drug discovery. This may be particularly important in the context of monogenic rare hereditary diseases, where iPSCs can provide an alternative model system to compensate for the lack of a predictive in-vitro human model for drug discovery.

United States is the largest Induced Pluripotent Stem Cells (iPSCs) market with about 43% market share. Europe is follower, accounting for about 33% market share.

The key players are Fujifilm Holding Corporation (CDI), Ncardia, Sumitomo Dainippon Pharma, Astellas Pharma Inc, Fate Therapeutics, Inc, Pluricell Biotech, Cell Inspire Biotechnology, ReproCELL etc. Top 3 companies occupied about 73% market share.

This report is a detailed and comprehensive analysis for global Induced Pluripotent Stem Cells (iPSCs) market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Induced Pluripotent Stem Cells (iPSCs) market size and forecasts, in consumption value ($ Million), 2020-2031

Global Induced Pluripotent Stem Cells (iPSCs) market size and forecasts by region and country, in consumption value ($ Million), 2020-2031

Global Induced Pluripotent Stem Cells (iPSCs) market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031

Global Induced Pluripotent Stem Cells (iPSCs) market shares of main players, in revenue ($ Million), 2020-2025

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Induced Pluripotent Stem Cells (iPSCs)

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Induced Pluripotent Stem Cells (iPSCs) market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Fujifilm Holding Corporation (CDI), Ncardia, Sumitomo Dainippon Pharma, Astellas Pharma Inc, Fate Therapeutics, Inc, Pluricell Biotech, Cell Inspire Biotechnology, ReproCELL, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market segmentation

Induced Pluripotent Stem Cells (iPSCs) market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Human iPSCs
Mouse iPSCs

Market segment by Application
Academic Research
Drug Development and Discovery
Toxicity Screening
Regenerative Medicine
Others

Market segment by players, this report covers
Fujifilm Holding Corporation (CDI)
Ncardia
Sumitomo Dainippon Pharma
Astellas Pharma Inc
Fate Therapeutics, Inc
Pluricell Biotech
Cell Inspire Biotechnology
ReproCELL

Market segment by regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Induced Pluripotent Stem Cells (iPSCs) product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Induced Pluripotent Stem Cells (iPSCs), with revenue, gross margin, and global market share of Induced Pluripotent Stem Cells (iPSCs) from 2020 to 2025.

Chapter 3, the Induced Pluripotent Stem Cells (iPSCs) competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Induced Pluripotent Stem Cells (iPSCs) market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Induced Pluripotent Stem Cells (iPSCs).

Chapter 13, to describe Induced Pluripotent Stem Cells (iPSCs) research findings and conclusion.